SCHEMBL5135930

SCHEMBL5135930

CCCCN(Cc1ccc(O)cc1Cl)Cc1c(-c2ccccc2OC)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.36
CRHR1 P34998 2/20 0.36
CASR P41180 1/20 0.35
BCHE P06276 5/20 0.35
BCL2L2 Q92843 1/20 0.35
HTR1A P08908 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
PAX8 Q06710 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ACHE P22303 3/20 0.34
MAOB P27338 2/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TSHR P16473 2/20 0.33
TAAR1 Q96RJ0 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136452 0.94 HDAC1 (0.36) C5AR1CRHR1BCHEBCL2L2HTR1A
SCHEMBL5137492 0.89 C5AR1 (0.42) C5AR1CRHR1MEN1KMT2AGAA
SCHEMBL5136819 0.88 TSPO (0.40) C5AR1CRHR1BCHEMEN1KMT2A
SCHEMBL5138077 0.87 C5AR1 (0.39) C5AR1CRHR1CASRBCHEBCL2L2
SCHEMBL5136565 0.87 BCL2L2 (0.36) C5AR1BCHEBCL2L2HTR1AHTR2C
SCHEMBL5137101 0.86 BCHE (0.42) C5AR1CRHR1CASRBCHEBCL2L2
SCHEMBL5074977 0.86 C5AR1 (0.39) C5AR1CRHR1BCHEGAATSHR
SCHEMBL5074785 0.86 C5AR1 (0.40) C5AR1CRHR1TSHR
SCHEMBL4770190 0.86 TLR7 (0.38) C5AR1CRHR1MEN1KMT2AGAA
SCHEMBL5135984 0.84 BCL2L2 (0.39) C5AR1CRHR1CASRBCHEBCL2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed